Ampa raises $8.5m to begin US neuromodulation system launch
Ampa’s TMS is indicated for treating major depressive disorder in adults who have not responded adequately to prior antidepressant medications.
23 October 2025
23 October 2025
Ampa’s TMS is indicated for treating major depressive disorder in adults who have not responded adequately to prior antidepressant medications.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.